Disappointing Clinical Trial Pummels Acadia. (cover story)

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Subject Terms:
    • Subject Terms:
    • Abstract:
      The article reports on the failure of pimavanserin drug, developed by SorrentoValley, California-based Acadia Pharmaceuticals Inc., to prove its effectiveness to treat Parkinson's disease psychosis during the six-week, 300-person study. The result has led to the decline of Acadia's stock by two-thirds in September 2009. However, the company has continued to believe in the capacity of the drug despite the results.